Net Revenues (USD, thousands)

Cost of Sales (USD, thousands)

Research and Development Expenses (USD, thousands)

Selling, General and Administrative Expenses (USD, thousands)

Amortization of Acquired Intangible Assets (USD, thousands)

Total Operating Expenses, Net (USD, thousands)

Operating Income (Loss) (USD, thousands)

Interest Income (USD, thousands)

Changes in Fair Value of Trading Securities (USD, thousands)

Interest Expense (USD, thousands)

Income (Loss) Before Income Taxes (USD, thousands)

Income Tax Expense (Benefit) (USD, thousands)

Net Income (Loss) (USD, thousands)

Basic Earnings (Loss) per Share (USD)

Diluted Earnings (Loss) per Share (USD)

222d38826757faae161c3b1bc14dae26ad1db9ddb0a2a2a220f0bc04dedeeb2d

Cash and cash equivalents (USD, thousands)

Marketable investment securities (USD, thousands)

Accounts receivable, net (USD, thousands)

Inventory (USD, thousands)

Prepaid expenses and other current assets (USD, thousands)

Total current assets (USD, thousands)

Long-term accounts receivable, net (USD, thousands)

Property and equipment, net (USD, thousands)

Operating lease assets (USD, thousands)

Goodwill and other intangible assets, net (USD, thousands)

Other assets – long-term (USD, thousands)

Total assets (USD, thousands)

Accounts payable (USD, thousands)

Accrued compensation (USD, thousands)

Operating lease liabilities, current portion (USD, thousands)

Other accrued and current liabilities (USD, thousands)

Total current liabilities (USD, thousands)

Noncurrent operating lease liabilities (USD, thousands)

Total liabilities (USD, thousands)

Common stock (USD, thousands)

Additional paid-in capital (USD, thousands)

Accumulated deficit (USD, thousands)

Accumulated other comprehensive loss (USD, thousands)

Total stockholders’ equity (USD, thousands)

Total liabilities and stockholders’ equity (USD, thousands)

c2248cb6b91ceef9f6ad2bb822bdd1f0b0dda9af9339e93e099ddcca24a3510b

Number of test reports delivered for DecisionDx-Melanoma (Reports)

Number of test reports delivered for DecisionDx-SCC (Reports)

Number of test reports delivered for Diagnostic GEP offering (Reports)

Number of test reports delivered for Dermatologic Total (Reports)

Number of test reports delivered for DecisionDx-UM (Reports)

Number of test reports delivered for TissueCypher (Reports)

Number of test reports delivered for IDgenetix (Reports)

Number of test reports delivered (Grand Total) (Reports)

d2f896c3035ed8ee08d9cd48088786c78057144bf02affef26939aae4ad52922

Dermatologic Tests

- DecisionDx-Melanoma

- DecisionDx-SCC

- Diagnostic GEP Offering

Non-Dermatologic Tests

- TissueCypher

- DecisionDx-UM

- IDgenetix

Total Revenue

a3540d19546fa52075592443f0d143a9a08aad81982cf71d8fab373e960407b9

Net income (loss) [USD, thousands]

Depreciation and amortization [USD, thousands]

Stock-based compensation expense [USD, thousands]

Change in fair value of trading securities [USD, thousands]

Accretion of discounts on marketable investment securities [USD, thousands]

Other, operating activities [USD, thousands]

Net cash provided by (used in) operating activities [USD, thousands]

Purchases of marketable investment securities [USD, thousands]

Proceeds from maturities of marketable investment securities [USD, thousands]

Purchases of property and equipment [USD, thousands]

Proceeds from sale of property and equipment [USD, thousands]

Net cash used in investing activities [USD, thousands]

Proceeds from exercise of common stock options [USD, thousands]

Payment of employees’ taxes on vested restricted stock units [USD, thousands]

Proceeds from contributions to the employee stock purchase plan [USD, thousands]

Repayment of principal portion of finance lease liabilities [USD, thousands]

Proceeds from issuance of term debt [USD, thousands]

Net cash provided by (used in) financing activities [USD, thousands]

NET CHANGE IN CASH AND CASH EQUIVALENTS [USD, thousands]

Deferred income taxes [USD, thousands]

Beginning of year cash and cash equivalents [USD, thousands]

End of year cash and cash equivalents [USD, thousands]

47fe4c08fd633b4363133936c185854a2f0e05dcb38d51590d33a9d4f77da7c1

Castle Biosciences Inc (CSTL)

Financials